Mazahir Alimohamed
Stock Analyst at Oppenheimer
(2.67)
# 2,948
Out of 4,646 analysts
16
Total ratings
42.9%
Success rate
7.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mazahir Alimohamed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $97 → $100 | $68.88 | +45.18% | 3 | Aug 12, 2026 | |
| IKT Inhibikase Therapeutics | Maintained: Buy | $5 | $2.41 | +107.47% | 2 | Aug 12, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterated: Buy | $22 | $9.23 | +138.35% | 3 | Aug 12, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $50 | $25.02 | +99.84% | 2 | Jul 31, 2026 | |
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $82 | $32.41 | +153.01% | 1 | Jul 29, 2026 | |
| IFRX InflaRx | Reiterated: Buy | $9 | $2.01 | +347.76% | 3 | Jul 20, 2026 | |
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $8 | $2.54 | +214.96% | 1 | Jul 9, 2026 | |
| EWTX Edgewise Therapeutics | Initiated Coverage: Buy | $51 | $43.18 | +18.11% | 1 | Jul 9, 2026 |
Tarsus Pharmaceuticals
Aug 12, 2026
Reiterated: Buy
Price Target: $97 → $100
Current: $68.88
Upside: +45.18%
Inhibikase Therapeutics
Aug 12, 2026
Maintained: Buy
Price Target: $5
Current: $2.41
Upside: +107.47%
BridgeBio Oncology Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $22
Current: $9.23
Upside: +138.35%
Tyra Biosciences
Jul 31, 2026
Reiterated: Buy
Price Target: $50
Current: $25.02
Upside: +99.84%
Quince Therapeutics
Jul 29, 2026
Initiated Coverage: Buy
Price Target: $82
Current: $32.41
Upside: +153.01%
InflaRx
Jul 20, 2026
Reiterated: Buy
Price Target: $9
Current: $2.01
Upside: +347.76%
Connect Biopharma Holdings
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $2.54
Upside: +214.96%
Edgewise Therapeutics
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $43.18
Upside: +18.11%